The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses

Tammy Kielian, Mohsin Md Syed, Shuliang Liu, Nirmal K. Phulwani, Napoleon Phillips, Gail Wagoner, Paul D. Drew, Nilufer Esen

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Brain abscesses result from a pyogenic parenchymal infection commonly initiated by Gram-positive bacteria such as Staphylococcus aureus. Although the host immune response elicited following infection is essential for effective bacterial containment, this response also contributes to the significant loss of brain parenchyma by necrosis that may be reduced by modulating the inflammatory response. Ciglitazone, a PPAR-γ agonist with anti-inflammatory properties, was evaluated for its ability to influence the course of brain abscess development when treatment was initiated 3 days following infection. Interestingly, abscess-associated bacterial burdens were significantly lower following ciglitazone administration, which could be explained, in part, by the finding that ciglitazone enhanced S. aureus phagocytosis by microglia. In addition, ciglitazone attenuated the expression of select inflammatory mediators during brain abscess development including inducible NO synthase, TNF-α, IL-1β, CXCL2, and CCL3. Unexpectedly, ciglitazone also accelerated brain abscess encapsulation, which was typified by the heightened expression of fibronectin and α-smooth muscle actin-positive myofibroblasts. Collectively, through its ability to attenuate excessive inflammation and accelerate abscess encapsulation, ciglitazone may effectively sequester brain abscesses and limit bacterial dissemination.

Original languageEnglish (US)
Pages (from-to)5004-5016
Number of pages13
JournalJournal of Immunology
Volume180
Issue number7
StatePublished - Apr 1 2008

Fingerprint

Brain Abscess
Peroxisome Proliferator-Activated Receptors
Abscess
Staphylococcus aureus
Infection
Myofibroblasts
Microglia
Gram-Positive Bacteria
Interleukin-1
Fibronectins
Phagocytosis
Nitric Oxide Synthase
Smooth Muscle
ciglitazone
Actins
Anti-Inflammatory Agents
Necrosis
Inflammation
Brain

ASJC Scopus subject areas

  • Immunology

Cite this

The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. / Kielian, Tammy; Syed, Mohsin Md; Liu, Shuliang; Phulwani, Nirmal K.; Phillips, Napoleon; Wagoner, Gail; Drew, Paul D.; Esen, Nilufer.

In: Journal of Immunology, Vol. 180, No. 7, 01.04.2008, p. 5004-5016.

Research output: Contribution to journalArticle

Kielian, Tammy ; Syed, Mohsin Md ; Liu, Shuliang ; Phulwani, Nirmal K. ; Phillips, Napoleon ; Wagoner, Gail ; Drew, Paul D. ; Esen, Nilufer. / The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. In: Journal of Immunology. 2008 ; Vol. 180, No. 7. pp. 5004-5016.
@article{26bea168491f4cbe9d79c33293789971,
title = "The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses",
abstract = "Brain abscesses result from a pyogenic parenchymal infection commonly initiated by Gram-positive bacteria such as Staphylococcus aureus. Although the host immune response elicited following infection is essential for effective bacterial containment, this response also contributes to the significant loss of brain parenchyma by necrosis that may be reduced by modulating the inflammatory response. Ciglitazone, a PPAR-γ agonist with anti-inflammatory properties, was evaluated for its ability to influence the course of brain abscess development when treatment was initiated 3 days following infection. Interestingly, abscess-associated bacterial burdens were significantly lower following ciglitazone administration, which could be explained, in part, by the finding that ciglitazone enhanced S. aureus phagocytosis by microglia. In addition, ciglitazone attenuated the expression of select inflammatory mediators during brain abscess development including inducible NO synthase, TNF-α, IL-1β, CXCL2, and CCL3. Unexpectedly, ciglitazone also accelerated brain abscess encapsulation, which was typified by the heightened expression of fibronectin and α-smooth muscle actin-positive myofibroblasts. Collectively, through its ability to attenuate excessive inflammation and accelerate abscess encapsulation, ciglitazone may effectively sequester brain abscesses and limit bacterial dissemination.",
author = "Tammy Kielian and Syed, {Mohsin Md} and Shuliang Liu and Phulwani, {Nirmal K.} and Napoleon Phillips and Gail Wagoner and Drew, {Paul D.} and Nilufer Esen",
year = "2008",
month = "4",
day = "1",
language = "English (US)",
volume = "180",
pages = "5004--5016",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses

AU - Kielian, Tammy

AU - Syed, Mohsin Md

AU - Liu, Shuliang

AU - Phulwani, Nirmal K.

AU - Phillips, Napoleon

AU - Wagoner, Gail

AU - Drew, Paul D.

AU - Esen, Nilufer

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Brain abscesses result from a pyogenic parenchymal infection commonly initiated by Gram-positive bacteria such as Staphylococcus aureus. Although the host immune response elicited following infection is essential for effective bacterial containment, this response also contributes to the significant loss of brain parenchyma by necrosis that may be reduced by modulating the inflammatory response. Ciglitazone, a PPAR-γ agonist with anti-inflammatory properties, was evaluated for its ability to influence the course of brain abscess development when treatment was initiated 3 days following infection. Interestingly, abscess-associated bacterial burdens were significantly lower following ciglitazone administration, which could be explained, in part, by the finding that ciglitazone enhanced S. aureus phagocytosis by microglia. In addition, ciglitazone attenuated the expression of select inflammatory mediators during brain abscess development including inducible NO synthase, TNF-α, IL-1β, CXCL2, and CCL3. Unexpectedly, ciglitazone also accelerated brain abscess encapsulation, which was typified by the heightened expression of fibronectin and α-smooth muscle actin-positive myofibroblasts. Collectively, through its ability to attenuate excessive inflammation and accelerate abscess encapsulation, ciglitazone may effectively sequester brain abscesses and limit bacterial dissemination.

AB - Brain abscesses result from a pyogenic parenchymal infection commonly initiated by Gram-positive bacteria such as Staphylococcus aureus. Although the host immune response elicited following infection is essential for effective bacterial containment, this response also contributes to the significant loss of brain parenchyma by necrosis that may be reduced by modulating the inflammatory response. Ciglitazone, a PPAR-γ agonist with anti-inflammatory properties, was evaluated for its ability to influence the course of brain abscess development when treatment was initiated 3 days following infection. Interestingly, abscess-associated bacterial burdens were significantly lower following ciglitazone administration, which could be explained, in part, by the finding that ciglitazone enhanced S. aureus phagocytosis by microglia. In addition, ciglitazone attenuated the expression of select inflammatory mediators during brain abscess development including inducible NO synthase, TNF-α, IL-1β, CXCL2, and CCL3. Unexpectedly, ciglitazone also accelerated brain abscess encapsulation, which was typified by the heightened expression of fibronectin and α-smooth muscle actin-positive myofibroblasts. Collectively, through its ability to attenuate excessive inflammation and accelerate abscess encapsulation, ciglitazone may effectively sequester brain abscesses and limit bacterial dissemination.

UR - http://www.scopus.com/inward/record.url?scp=44449147861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449147861&partnerID=8YFLogxK

M3 - Article

C2 - 18354226

AN - SCOPUS:44449147861

VL - 180

SP - 5004

EP - 5016

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -